Antineoplastic Agents

All Drugs and Chemicals

Hypoglycemic Agents

Lipid Regulating Agents

Bone Density Conservation Agents

Apatinib

Metformin

Rosuvastatin Calcium

Calcium

Calcium, Dietary

Anticholesteremic Agents

Hypolipidemic Agents

Antimetabolites

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Enzyme Inhibitors

Protein Kinase Inhibitors

Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 7 and Apatinib at a dose of 250 mg once daily from Day 4 until Day 9.

Participant will be administered a single oral dose of metformin 500 milligram (mg) on Day 1 and Day 6 and Apatinib at a dose of 250 mg once daily from Day 3 until Day 7.

Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.

Apatinib in arm1

Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.

Rosuvastatin

Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.

Apatinib in arm2

Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.

The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib on Rosuvastatin or Metformin.

The secondary objective of the study was to assess the safety of Apatinib alone or Rosuvastatin/Metformin alone or concomitant medication.

A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.

Open-Label, Fixed-Sequence Study in Solid Tumor Subjects to Investigate the Pharmacokinetic Interaction Between Apatinib and Transporter Substrates Rosuvastatin and Metformin.

The Cmax is the maximum observed concentration

The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.

The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time

An adverse event is any untoward medical occurrence in a patient or clinical study participant criteria

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.	NCT04428086	Solid Tumor, Ad...	Apatinib in arm... Rosuvastatin Apatinib in arm... Metformin	18 Years - 70 Years	Jiangsu HengRui Medicine Co., Ltd.
A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.	NCT04428086	Solid Tumor, Ad...	Apatinib in arm... Rosuvastatin Apatinib in arm... Metformin	18 Years - 70 Years	Jiangsu HengRui Medicine Co., Ltd.

Spots Global Cancer Trial Database for apatinib in arm2